Clinical Trials
1,006 trialsARC-25
Arcus Biosciences, Inc.
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
BeOne Medicines
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Perspective Therapeutics
MAGE-A4ᶜ¹º³²T for Multi-Tumor
USWM, LLC (dba US WorldMeds)
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Eisai Inc.
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
xCures
Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected
Novartis
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
PIKALO-1
Eli Lilly and Company
A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
Incyte Corporation
panSOHO
Bayer
FLORENZA
AbbVie
FiREBOLT
Eli Lilly and Company
RAINFOL-01
Genmab
FONTANA
AstraZeneca
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)
EMD Serono
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Atavistik Bio, Inc
RAINFOLâ„¢-07
Genmab
A First-in-Human Study of HH160 in Patients With Advanced Solid Tumors
Huahui Health
Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.
Pfizer
BASECAMP-1
A2 Biotherapeutics Inc.
CERTIS1
AstraZeneca
GLORIOSA
AbbVie
MRD
Imunon
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
IDEAYA Biosciences
BARHYSTER
Aesculap AG
RAINFOL-02
Genmab
OVATION-3
Imunon
Embrace Gyn
Medtronic - MITG
RAINFOL-04
Genmab
RAINFOL-02
Genmab
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
Seagen Inc.
PRO1107 in Patients With Advanced Solid Tumors
Genmab
MAESTRA 1
Incyte Corporation
DP-04
AstraZeneca
MAESTRA 2
Incyte Corporation
DUAL-OV-CAR-NK
Beijing Biotech
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Eli Lilly and Company
TroFuse-022
Merck Sharp & Dohme LLC
TroFuse-021
Merck Sharp & Dohme LLC
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor
Shenzhen Ionova Life Sciences Co., Ltd.
A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies
Zelluna Immunotherapy AS
OVARD
AstraZeneca
Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer
Nerviano Medical Sciences
OLIVIA
AstraZeneca
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
Shenzhen Ionova Life Sciences Co., Ltd.
STARTRK-2
Hoffmann-La Roche
NAPISTAR1-01
Tubulis GmbH
FRAmework-01
Eli Lilly and Company
A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
GlaxoSmithKline